About Deep Genomics
Deep Genomics is a company based in Toronto (Canada) founded in 2015. Deep Genomics has raised $237.96 million across 4 funding rounds from investors including Fidelity Investments, ARE and Khosla Ventures. Deep Genomics offers products and services including AI Platform, BigRNA, and BigRNA+. Deep Genomics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Toronto, Canada
- SectorsHealthcare
- Email••••••••
- Website deepgenomics.com
- Social LinkedIn X Facebook
- Total Equity Funding$237.96 M (USD)
in 4 rounds
- Latest Funding Round$180 M (USD), Series C
Jul 2021
- InvestorsFidelity Investments
& 12 more
Products & Services of Deep Genomics
Deep Genomics offers a comprehensive portfolio of products and services, including AI Platform, BigRNA, and BigRNA+.
Uses AI to identify RNA targets and evaluate therapies for genetic conditions.
Foundation model for analyzing RNA biology and discovering new mechanisms.
Expanded model for pursuing complex genetic diseases and novel targets.
Funding Insights of Deep Genomics
Deep Genomics has successfully raised a total of $237.96M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $180 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $238.0M
- Total Rounds 4
- Last Round Series C — $180.0M
- First Round $5.0M
(Nov 2015)
- Investors Count 13
All 4 funding rounds of Deep Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $180.0M | Series C | – | SoftBank Vision Fund | |
| Jan 2020 | $40.0M | Series B | – | Future Ventures | |
| Sep 2017 | $13.0M | Series A | – | Khosla Ventures | |
| Nov 2015 | $5.0M | Seed | – | True Ventures |
13 investors in total: 13 institutional.
Investors in Deep Genomics
Deep Genomics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Venture capital investments are made in precision medicine companies. | – | amplitudevc.com | Montreal, Canada | |
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital firm supporting AI founders through investments and community. | – | trueventures.com | - | |
Magnetic Ventures is focused on transforming healthcare through AI and biotech investments. | 2018 | magneticvc.com | - | |
Future Ventures is focused on early-stage venture capital investments. | – | future.ventures | Los Altos, United States | |
Venture capital investments are directed toward multiple sectors. | – | njfcapital.com | London, United Kingdom | |
Multiple sectors are invested in by the private equity firm. | 1996 | kcpl.ca | Toronto, Canada | |
Corporate backed venture capital firm focused on multiple sectors | – | bloombergbeta.com | San Francisco, United States | |
Pension fund assets are managed for sustainable long-term growth. | 1997 | cppinvestments.com | Toronto, Canada |
Investor details for Deep Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Deep Genomics
33 people are tracked at Deep Genomics (12 in leadership, 12 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Brian O'Callaghan | CEO | Leadership |
Emily Lee Mshr | Vp, Human Resources | Leadership |
Asha Rostamianfar | Director, Software & Data Engineering | Leadership |
David B. Johnston | Chief Financial Officer | Leadership |
Radu Dobrin | CTO | Leadership |
Clive Bertram | Chief Business Officer | Leadership |
Tom Masterson | COO | Leadership |
Matt Cahill | Chief Strategy Officer | Leadership |
Marta Wierzbicka Verby | Director Of Laboratory Operations | Leadership |
Monika Kowalczyk | Vp, Platform Technologies | Leadership |
Tom Peters | Director Of Legal | Leadership |
Greg Hoffman | Chief Scientic Officer | Leadership |
Yann Lecun | Advisor | Board & advisors |
Steven F. Dowdy | Advisor | Board & advisors |
Benjamin Neale | Advisor | Board & advisors |
Maryanna Saenko | Director | Board & advisors |
Dion Madsen | Director | Board & advisors |
Adam D'Augelli | Director | Board & advisors |
Masad Damha | Advisor | Board & advisors |
Mark Edbrooke | Advisor | Board & advisors |
13 more people are available in the full profile.
Complete people profiles for Deep Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Deep Genomics
3 dated milestones of Deep Genomics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Deep Genomics is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series C, of $180.0M.
Competitors of Deep Genomics
Deep Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347.0M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.3M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| poseida.com | 2015 | San Diego, United States | $323.8M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.7M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.2M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206.0M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| formatherapeutics.com | 2007 | Watertown, United States | $417.6M | 165 | Developer of therapeutic solutions for multiple health purposes | |
| celsiustx.com | 2018 | Cambridge, United States | $148.0M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.0M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. |
Detailed competitors of Deep Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Deep Genomics
The website of Deep Genomics (deepgenomics.com) receives about 11.1K visits a month.
- Monthly visits11.1K
▼ 28.6% vs previous month
Latest news on Deep Genomics
Complete news archive for Deep Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Deep Genomics
10 companies that operate in the same segment as Deep Genomics (Clinical Genomics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Panomic profiling technologies are developed for cancer precision medicine. | 1996 | Irving, Texas, United States | USD 1.23 B | – | 1,339 | |
Genomics-based diagnostic tests for cancer are provided. | 2010 | Cambridge, Massachusetts, United States | USD 96.5 M | – | – | |
Digital molecular biology analytics are developed for disease management. | 2012 | Carlsbad, California, United States | USD 95.02 M | – | 46 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Genomic database for clinical research is provided. | 2015 | San Francisco, California, United States | USD 435 M | – | – | |
Genomic sequencing and diagnosis software is provided for healthcare. | 2011 | Menlo Park, California, United States | USD 87.3 M | USD 69.65 M | 229 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Deep Genomics
Deep Genomics was founded in 2015.
Deep Genomics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Deep Genomics is a funded company, having raised a total of $237.96M across 4 funding rounds to date. The company's 1st funding round was a Seed of $5M, raised on Nov 2015.
Deep Genomics has expertise in machine learning, genome biology and precision medicine. They are working on a new generation of computational technologies that can tell what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic using machine learning and deep learning techniques. Their first product is SPIDEX, a comprehensive set of mutations and their predicted effects on RNA splicing across the entire human genome. They are making the SPIDEX database free for non-commercial purposes.
Deep Genomics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Deep Genomics offers AI Platform, BigRNA, and BigRNA+.
Deep Genomics has 13 investors. Key investors include Fidelity Investments, ARE, Khosla Ventures, CPP Investments, and Kensington Capital Partners.